RxDoctor Payments Data

Kenneth Santiago, MD

Internal Medicine · Conway, SCNPI 1801878186

Payments from drug & device makers

$659in general payments, 2019–2025

Across 10 payments — averaging $65.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$252
  • AstraZeneca$125
  • Avanir Pharmaceuticals, Inc.$114
  • Abbott$111
  • Pfizer$16
  • Johnson & Johnson$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$447,769
Medicare patients
926
Services billed
5,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban890$209,205
TrulicityDulaglutide39$39,105
FarxigaDapagliflozin Propanediol122$21,907
JanuviaSitagliptin Phosphate127$21,084
Cinacalcet Hcl19$14,876
MyrbetriqMirabegron76$14,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,397
Atorvastatin Calcium946$12,204
TresibaInsulin Degludec16$11,222
LinzessLinaclotide18$10,380
GemtesaVibegron76$10,207
Duloxetine Hcl245$8,246
XareltoRivaroxaban36$8,069
Pantoprazole Sodium363$7,782
Gabapentin493$7,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$209,205890 claims
AstraZenecaFarxiga, Brilinta, Symbicort$125$31,422176 claims
Johnson & JohnsonXarelto$14$8,06936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →